The identification of NPC disease-like phenotypes, alongside the established interaction between NPC2 and DHDDS proteins [18], raises the possibility that therapeutics approved for NPC could also be beneficial to DHDDS and indeed NUS1. This evidence concerns the gene NPC2 and nasopharyngeal carcinoma.